- Report
- January 2026
- 187 Pages
Global
From €3137EUR$3,545USD£2,688GBP
€3485EUR$3,939USD£2,987GBP
- Report
- January 2026
- 194 Pages
Global
From €3137EUR$3,545USD£2,688GBP
€3485EUR$3,939USD£2,987GBP
- Report
- February 2026
- 250 Pages
Global
From €3973EUR$4,490USD£3,404GBP
- Report
- April 2026
- 200 Pages
Global
From €2646EUR$2,990USD£2,267GBP
- Report
- January 2026
- 188 Pages
Global
From €3137EUR$3,545USD£2,688GBP
€3485EUR$3,939USD£2,987GBP
- Report
- August 2026
- 196 Pages
Global
From €3137EUR$3,545USD£2,688GBP
€3485EUR$3,939USD£2,987GBP
- Report
- August 2026
- 181 Pages
Global
From €3137EUR$3,545USD£2,688GBP
€3485EUR$3,939USD£2,987GBP
- Report
- August 2026
- 281 Pages
Global
From €5176EUR$5,850USD£4,436GBP
- Report
- August 2026
- 189 Pages
Global
From €5176EUR$5,850USD£4,436GBP
- Report
- February 2026
- 250 Pages
Global
From €3973EUR$4,490USD£3,404GBP
- Report
- February 2026
- 250 Pages
Global
From €3973EUR$4,490USD£3,404GBP
- Report
- February 2026
- 250 Pages
Global
From €3973EUR$4,490USD£3,404GBP
- Report
- February 2026
- 250 Pages
Global
From €3973EUR$4,490USD£3,404GBP
- Report
- May 2026
- 180 Pages
Global
From €3982EUR$4,500USD£3,412GBP
- Report
- December 2025
- 200 Pages
Global
From €7034EUR$7,950USD£6,028GBP
- Clinical Trials
- April 2026
- 280 Pages
Global
From €2654EUR$3,000USD£2,275GBP
- Report
- May 2026
- 100 Pages
Global
From €2388EUR$2,699USD£2,046GBP
- Drug Pipelines
- May 2026
- 150 Pages
Global
From €2468EUR$2,789USD£2,115GBP
- Report
- April 2026
- 148 Pages
Global
From €2654EUR$2,999USD£2,274GBP
€3538EUR$3,999USD£3,032GBP
- Report
- October 2025
- 160 Pages
Global
From €2796EUR$3,160USD£2,396GBP
€3495EUR$3,950USD£2,995GBP

Memantine is a drug used to treat symptoms of Alzheimer's disease and other forms of dementia. It is classified as an NMDA receptor antagonist, which works by blocking the action of a neurotransmitter called glutamate. This helps to reduce the symptoms of dementia, such as memory loss, confusion, and difficulty with language. Memantine is also used to treat Parkinson's disease, Huntington's disease, and multiple sclerosis.
Memantine is a relatively new drug, having been approved by the FDA in 2003. It is available in both oral and intravenous forms, and is typically prescribed in combination with other drugs. It is generally well-tolerated, with few side effects.
The memantine market is a growing one, with a number of companies offering products. These include Novartis, Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Other companies, such as Actavis, Lupin, and Dr. Reddy's Laboratories, also offer generic versions of the drug. Show Less Read more